Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis

OBJECTIVE: Baricitinib is an orally administered inhibitor of JAK1 and JAK2 that has been shown to be effective in treating rheumatoid arthritis (RA). This study was undertaken to analyze changes in lymphocyte cell subsets during baricitinib treatment and to correlate these changes with clinical out...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Arthritis Rheumatol
Auteurs principaux: Tanaka, Yoshiya, McInnes, Iain B., Taylor, Peter C., Byers, Nicole L., Chen, Lei, de Bono, Stephanie, Issa, Maher, Macias, William L., Rogai, Veronica, Rooney, Terence P., Schlichting, Douglas E., Zuckerman, Steven H., Emery, Paul
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2018
Sujets:
Rheumatoid Arthritis
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6587754/
https://ncbi.nlm.nih.gov/pubmed/30058112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40680
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires